Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

UGT1A6 variants and deferiprone-induced ADRs: a complication-specific analysis in Iranian thalassemia patients.

Pharmacogenomics - 1 Jan 2025

Najaflu Malihe, Neufeld Ellis J, Mansourian Marjan, Ghanavat Majid, Salehi Mansoor

Abstract excerpt

AIMS: Deferiprone, an iron chelator, causes variable adverse drug reactions (ADRs) in β-thalassemia patients, suggesting a role for pharmacogenetic factors. To address the lack of comprehensive pharmacogenetic data, this study investigated the association between four common UGT1A6 variants - the primary enzyme metabolizing deferiprone - and the occurrence of specific ADRs, considering relevant clinical and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta-Thalassemia
Share to Child
Share to Drug-Related Side Effects and Adverse Reactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucuronosyltransferase

Share to Haplotypes

Share to Iron Chelating Agents

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 41622710
DOI: 10.1080/14622416.2025.2608573
PMCID: PMC12915808

Genes

UGT1A6
GC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

UGT1A6 variants and deferiprone-induced ADRs: a complication-specific analysis in Iranian thalassemia patients.PMID 41622710Read ↗

Three most common nonsynonymous UGT1A6*2 polymorphisms (Thr181Ala, Arg184Ser and Ser7Ala) and therapeutic response to deferiprone in β-thalassemia major patients.Semantic proximity Read ↗

Pharmacogenetic Study of Deferasirox, an Iron Chelating AgentSemantic proximity Read ↗

Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants.Semantic proximity Read ↗

Deferiprone Related Bone Disease May Be Related to Associated Gilbert SyndromeSemantic proximity Read ↗

Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients.Semantic proximity Read ↗

Cytochrome P450 2D6 (CYP2D6) and glucose-6-phosphate dehydrogenase (G6PD) genetic variations in Thai vivax malaria patients: Implications for 8-aminoquinoline radical cure.Semantic proximity Read ↗

UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteers.Semantic proximity Read ↗

Role of pharmacogenetics on deferasirox AUC and efficacy.Semantic proximity Read ↗

Pharmacogenomic and Clinical Predictors of Deferasirox Response in Transfusion-Dependent Thalassemia Identified Using Whole-Genome Sequencing.Semantic proximity Read ↗

Impact of SNP Variants in PON-1 or UGT1A1 on Iron Chelation Therapy Outcomes and Zinc Status in Thalassemia Major Patients.Semantic proximity Read ↗

Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis.Semantic proximity Read ↗

Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.